323 related articles for article (PubMed ID: 7536126)
1. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation.
Critz FA; Tarlton RS; Holladay DA
Cancer; 1995 May; 75(9):2383-91. PubMed ID: 7536126
[TBL] [Abstract][Full Text] [Related]
2. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
Stokes SH
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer.
Critz FA; Levinson AK; Williams WH; Holladay DA
J Clin Oncol; 1996 Nov; 14(11):2893-900. PubMed ID: 8918485
[TBL] [Abstract][Full Text] [Related]
4. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Wein A; Tomaszewski JE; Coleman CN
Cancer; 1998 Jan; 82(2):334-41. PubMed ID: 9445191
[TBL] [Abstract][Full Text] [Related]
5. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.
Ragde H; Elgamal AA; Snow PB; Brandt J; Bartolucci AA; Nadir BS; Korb LJ
Cancer; 1998 Sep; 83(5):989-1001. PubMed ID: 9731904
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous radiotherapy for prostate cancer: 125I prostate implant followed by external-beam radiation.
Critz FA; Levinson AK; Williams WH; Holladay CT; Griffin VD; Holladay DA
Cancer J Sci Am; 1998; 4(6):359-63. PubMed ID: 9853134
[TBL] [Abstract][Full Text] [Related]
7. Prostate brachytherapy: treatment strategies.
Stone NN; Stock RG
J Urol; 1999 Aug; 162(2):421-6. PubMed ID: 10411050
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Zagars GK
J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
[TBL] [Abstract][Full Text] [Related]
9. [Long-term follow-up of serum prostate-specific antigen after radiotherapy of prostatic carcinoma].
Schmid HP; Ferrari MK; Stamey TA
Helv Chir Acta; 1994 Dec; 60(6):1101-5. PubMed ID: 7533148
[TBL] [Abstract][Full Text] [Related]
10. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.
Critz FA; Williams WH; Levinson AK; Benton JB; Schnell FJ; Holladay CT; Shrake PD
J Urol; 2003 Nov; 170(5):1864-7. PubMed ID: 14532794
[TBL] [Abstract][Full Text] [Related]
11. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma.
Ragde H; Blasko JC; Grimm PD; Kenny GM; Sylvester JE; Hoak DC; Landin K; Cavanagh W
Cancer; 1997 Aug; 80(3):442-53. PubMed ID: 9241078
[TBL] [Abstract][Full Text] [Related]
12. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
13. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation.
Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E
Cancer J; 2002; 8(4):322-7. PubMed ID: 12184410
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques.
Critz FA; Williams WH; Levinson AK; Benton JB; Holladay CT; Schnell FJ
J Urol; 2000 Sep; 164(3 Pt 1):738-41; discussion 741-3. PubMed ID: 10953137
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer.
Critz FA; Levinson K; Williams WH; Holladay D; Holladay C; Griffin V
Urology; 1997 May; 49(5):668-72. PubMed ID: 9145968
[TBL] [Abstract][Full Text] [Related]
17. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the local control in lymph-node staged localized prostate cancer treated by external beam radiotherapy, assessed by digital rectal examination, serum prostate-specific antigen and biopsy.
Borghede G; Aldenborg F; Wurzinger E; Johansson KA; Hedelin H
Br J Urol; 1997 Aug; 80(2):247-55. PubMed ID: 9284197
[TBL] [Abstract][Full Text] [Related]
19. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma.
Aref I; Eapen L; Agboola O; Cross P
Radiother Oncol; 1998 Aug; 48(2):203-7. PubMed ID: 9783893
[TBL] [Abstract][Full Text] [Related]
20. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up.
Medini E; Medini I; Reddy PK; Levitt SH
Cancer; 1996 Sep; 78(6):1254-9. PubMed ID: 8826948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
